ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 12, 2021, serves as a current report for ENDRA Life Sciences Inc., a Delaware corporation and emerging growth company. The filing references the company's financial results for the quarter ended June 30, 2021, which were announced via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the referenced press release (Exhibit 99.1) but are not included in the body of this Form 8-K.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It solely acts as a notification that the Q2 2021 results have been released.
Guidance, Outlook, and Risks
The text contains no management commentary, forward-looking guidance, specific risk factors, or discussion of unusual items. The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2021) for actual Q2 2021 financial figures.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbols (NDRA for Common Stock, NDRAW for Warrants) on The Nasdaq Stock Market LLC.
- Check subsequent filings for any updates to the financial data referenced in this report.